Abstract Since dietary restrictions and phosphorus Introduction removal by haemodialysis (HD) are not sufficient to control serum phosphate (s-phosphate) levels in dialysis Virtually all patients on chronic haemodialysis (HD) patients the use of oral phosphate binders is mandat-develop hyperphosphataemia with its known detriory. Calcium ketoglutarate (CaKE ) is an analogue of mental impact on the progression of secondary hyperglutamic acid exerting phosphate binding properties. parathyroidism, renal osteodystrophy and vascular Therefore we compared this substance to calcium calcifications [1,2]. Since the surplus of phosphorus acetate (CaAC ) in a 24-weeks open cross-over trial in can not sufficiently be removed by HD or reasonably 28 maintenance HD patients. Medications and HD restricted by dietary means the use of oral phosphate prescriptions were kept unchanged during the trial.
Mannheim and the Dialysis Centre Drs Zimmermann/ range in our laboratory is 2-6 pmol/l. All other parameters Wassmer, Mannheim, Germany. All patients had chronic were determined by standard techniques. renal failure and were on maintenance HD for at least 12 months. Thirty two stable chronic HD patients were enrolled after giving informed consent. Inclusion criteria were hyper-Statistics phosphataemia after withdrawal of phosphate binding agents (s-phosphorus >1.7 mmol/l ), known adherence to therapy, Thirty-two patients were originally enrolled in the trial. prior dialysis time >12 months and an intact PTH level Statistical analysis was performed on 28 patients who comsmaller than the ten-fold upper normal level. Previously, pleted the whole study (10 women, 18 only for the purpose of this study in a special 2900 mg From the eighth week on there was a tendency towards soluble granulate form containing 860 mg ketoglutarate and 240 mg Ca2+ in order to facilitate the prescription of equimo-lower s-phosphate levels in the CaAC group, however lar amounts of Ca2+. Prior to use, the granulate was dissolved these differences never reached a statistically significant in 25-50 ml of water. Dosages of both drugs followed an level ( Figures 1 and 2 ). In both groups there was an empirical formula [3] depending on s-phosphate levels at the unsignificant increase in s-calcium concentrations end of the withdrawal period, body weight and the thus during the study periods (Figure 3 ). The incidence of calculated 'phosphate surplus' (PS ): PS units=(change hypercalcaemia was not different between the groups s-phosphate mmol/l exceeding 1.4 mmol/l )×body weight when defined as s-calcium levels >2.6 mmol/l (CaAC: in kg. Each 20 units of PS correspond to 1×2 capsules of 16 episodes of 168 measurements; CaKE: 14 of 168, CaAC or 1×1 soluble granulate of CaKE both containing a total amount of 240 mg Ca2+ (example: s-phosphate 2.4, P=NS ). However, more severe hypercalcaemia body weight 60 kg; change=2.4 mmol/l−1.4 mmol/l= defined as s-calcium levels of>2.8 mmol/l occurred 1 mmol/l, 1 mmol/l×60 kg=60 units PS, 60 units/20=3= significantly more in CaAC treated patients when 3×2 capsules CaAC or 3×1 granulate CaKE ). After the compared to CaKE (eight episodes of 168 measureinitial prescription, the dosages of both substances were kept ments vs 1 of 168, P<0.05). The amount of ingested constant during each study period. No dose adjustments Ca2+ per day was not significantly different between were made in case normal s-phosphate levels were not the groups (CaAC 851±473 vs CaKE 920±571 mg).
achieved. Serum analysis included predialysis determination Intact PTH, calcitriol, albumin and venous bicarbonate of baseline values at the end of withdrawal followed by 2-weekly predialysis controls of phosphate, calcium and levels were neither significantly different between the venous bicarbonate levels. Intact PTH, calcitriol and groups at study entry or after 12 weeks treatment s-albumine values were obtained at the start and at the end ( Table 1) In this open randomized cross over study in 28 chronic Laboratory methods haemodialysis patients we demonstrated clearly that CaKE, when given in equimolar amounts of Ca2+, Intact PTH was measured by RIA (Nichols Institute Diagnostika GmbH, Bad Nauheim, Germany). The normal exerts the same phosphate binding effect as CaAC. Despite a stable significant reduction of s-phosphate small amount of prescribed Ca2+ (CaAC 851±473 vs CaKE 920±571 mg, n.s.) which was not significantly levels over the whole study time in both groups normal s-phosphate levels were not reached because the initial different between the groups. Generally, more than a two-fold amount of Ca2+ is required both for CaAC dosage based on an empirical formula was too small and we did not change the initial dosage since we and CaKE to decrease s-phosphate levels back in the normal range [2, 8] . Thus, despite the significant reducwanted to compare both substances given in equimolar amounts of Ca2+. This is reflected by the relatively tion of serum phosphorus induced by both agents [8] reported a high incidence of gastrointestinal complaints in haemodialysis patients receiving our study.
The incidence of severe hypercalcaemia defined as CaKE. In their study comparing CaKE to calcium carbonate in an open cross over design 29% patients s-calcium level of >2.8 mmol/l was significantly higher in CaAC treated patients when compared to CaKE. were withdrawn from CaKE therapy within the first 2 weeks due to gastrointestinal symptoms like vomiting, Recently, it was demonstrated in an unblinded crossover study of 10 patients, that CaKE had the same anorexia and diarrhoea. However, Bro et al. stated also that all of these patients had pre-existing gastroinphosphate binding capacity but induced significantly lesser increments in s-calcium levels when compared testinal symptoms. In contrast, none of our patients in the CaKE limb developed these symptoms. In our to CaCA [8] . This in vivo finding corresponds to in vitro findings, that CaKE has a similar phosphate-centres CaKE had been used for about 10 years and it is our general impression that it is a very well binding effect as CaCA with a smaller amount of Ca2+ available for resorption [9] . Furthermore, tolerated drug with no special gastrointestinal side effects. This is supported by studies from Zimmermann Zimmermann et al. in their two reports of successful use of CaKE as an phosphate binding agents reported and Riedel who also reported no gastrointestinal complaints using CaKE in a similar dosage of 900-1000 mg no occurrence of significant hypercalcaemia [3, 4] . Thus CaKE showed the same phosphate binding potency as elemental calcium per day in haemodialysis patients treated up to 36 months [3] [4] [5] . Nevertheless, the dosage the two well established phosphate binders CaCA and CaAC. However, the propensity of CaCA to increase of elemental calcium which was used in these studies as well as in our study was rather low and not sufficient s-calcium levels or of CaAC to induce hypercalcaemia seems not to be shared by CaKE making it the ideal to control phosphate levels. Thus, besides the possibility that CaKE is not well tolerated in patients with agent for patients prone to hypercalcaemia.
